09:53 AM EST - Helix BioPharma Corp. : announced that it has received approval from the Central Register of Clinical Trials at the Polish Ministry of Health of its European clinical trial application to perform the Company's planned Phase I/II clinical safety, tolerability and preliminary efficacy study of its lung cancer drug candidate, L-DOS47. Helix BioPharma Corp.
shares T.HBP are trading even at $2.56.
